Distribution of MPL and JAK2 mutations according to MPN diagnosis in the Pavia cohort
| Diagnosis . | JAK2 (V617F)–mutated (n = 533) . | MPL exon 10–mutated (n = 43) . | JAK2 (V617F)/MPL–unmutated (n = 316) . | All patients (n = 892) . |
|---|---|---|---|---|
| Essential thrombocythemia | 399 (60%) | 26* (4%) | 236 (36%) | 661 |
| Primary myelofibrosis | 114 (61%) | 10 (5%) | 63 (34%) | 187 |
| Post-essential thrombocythemia myelofibrosis | 20 (45%) | 7 (16%) | 17 (39%) | 44 |
| Diagnosis . | JAK2 (V617F)–mutated (n = 533) . | MPL exon 10–mutated (n = 43) . | JAK2 (V617F)/MPL–unmutated (n = 316) . | All patients (n = 892) . |
|---|---|---|---|---|
| Essential thrombocythemia | 399 (60%) | 26* (4%) | 236 (36%) | 661 |
| Primary myelofibrosis | 114 (61%) | 10 (5%) | 63 (34%) | 187 |
| Post-essential thrombocythemia myelofibrosis | 20 (45%) | 7 (16%) | 17 (39%) | 44 |
One patient with essential thrombocythemia carried both MPL and JAK2 (V617F) mutations; in subsequent analyses, this patient was included in the MPL group.